These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 19632099

  • 1. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
    Arca M, Cambuli VM, Montali A, Sentinelli F, Filippi E, Campagna F, Quagliarini F, Antonini R, Romeo S, Baroni MG.
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):660-6. PubMed ID: 19632099
    [Abstract] [Full Text] [Related]

  • 2. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
    Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, Antonini TM, Antonini R, Diczfalusy U, Iuliano L.
    Free Radic Biol Med; 2007 Mar 01; 42(5):698-705. PubMed ID: 17291993
    [Abstract] [Full Text] [Related]

  • 3. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 01; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 4. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B.
    Int J Clin Pharmacol Ther; 2012 Nov 01; 50(11):805-13. PubMed ID: 22943927
    [Abstract] [Full Text] [Related]

  • 5. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 01; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 6. Five-year follow-up of waist circumference, insulin and ALT levels in familial combined hyperlipidaemia.
    Brouwers MC, van Greevenbroek MM, Vermeulen VM, van Lin JM, van der Kallen CJ, de Bruin TW.
    Clin Sci (Lond); 2007 Nov 01; 113(9):375-81. PubMed ID: 17564583
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
    Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R.
    Am Heart J; 2002 Oct 01; 144(4):E6. PubMed ID: 12360175
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 01; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 9. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
    Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, Manzato E, Bittolo Bon G, Fellin R.
    Nutr Metab Cardiovasc Dis; 2005 Feb 01; 15(1):47-55. PubMed ID: 15871851
    [Abstract] [Full Text] [Related]

  • 10. Abdominal obesity and expression of familial combined hyperlipidemia.
    van der Kallen CJ, Voors-Pette C, de Bruin TW.
    Obes Res; 2004 Dec 01; 12(12):2054-61. PubMed ID: 15687407
    [Abstract] [Full Text] [Related]

  • 11. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
    Blanco-Colio LM, Martín-Ventura JL, Sol JM, Díaz C, Hernández G, Egido J.
    J Am Coll Cardiol; 2004 Apr 07; 43(7):1188-94. PubMed ID: 15063428
    [Abstract] [Full Text] [Related]

  • 12. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 07; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 13. Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia.
    Castro Cabezas M, Verseyden C, Meijssen S, Jansen H, Erkelens DW.
    J Clin Endocrinol Metab; 2004 Dec 07; 89(12):5972-80. PubMed ID: 15579746
    [Abstract] [Full Text] [Related]

  • 14. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 07; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 15. Waist circumference and serum adiponectin levels in obese and non-obese postmenopausal women.
    Milewicz A, Jedrzejuk D, Dunajska K, Lwow F.
    Maturitas; 2010 Mar 07; 65(3):272-5. PubMed ID: 20004538
    [Abstract] [Full Text] [Related]

  • 16. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia.
    Verseyden C, Meijssen S, Cabezas MC.
    J Clin Endocrinol Metab; 2004 Oct 07; 89(10):5021-9. PubMed ID: 15472200
    [Abstract] [Full Text] [Related]

  • 17. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.
    Am J Cardiol; 2006 Mar 01; 97(5):646-50. PubMed ID: 16490430
    [Abstract] [Full Text] [Related]

  • 18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 01; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 19. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
    Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Egido J.
    Eur J Pharmacol; 2008 May 31; 586(1-3):259-65. PubMed ID: 18374327
    [Abstract] [Full Text] [Related]

  • 20. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.
    Transplant Proc; 2005 Nov 31; 37(9):3808-12. PubMed ID: 16386546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.